Dr. Xiubao Ren: Exploring Tumor Immunotherapy from a “Reverse” Perspective – The Practice of Reverse Immune Editing Therapy

Dr. Xiubao Ren: Exploring Tumor Immunotherapy from a “Reverse” Perspective – The Practice of Reverse Immune Editing Therapy

The 5th Tianjin International Lymphoma Conference was successfully held from September 6 to 8, 2024. The conference featured 12 specialized sessions, including immunotherapy, basic translational research, and new drug development, providing a platform for international academic exchange and collaboration. During the event, Hematology Frontier invited Dr. Xiubao Ren from Tianjin Medical University Cancer Institute and Hospital to share insights on the progress of clinical trials in reverse immune editing therapy and its future application prospects in cancer treatment.
Peking Cancer Hospital Team’s PD-1/CTLA-4 Dual-Target Antibody Combined with Chemotherapy as First-Line Treatment for Advanced Gastric Cancer

Peking Cancer Hospital Team’s PD-1/CTLA-4 Dual-Target Antibody Combined with Chemotherapy as First-Line Treatment for Advanced Gastric Cancer

Dr. Jiafu Ji, Dr. Ziyu Li, and Dr.  Lin Shen from Peking Cancer Hospital have co-authored a research paper titled “Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial”, published online in Nature Medicine. The study addresses several critical clinical issues, such as the limited benefit of PD-1 monoclonal antibody treatment, the high incidence of adverse effects with PD-1 and CTLA-4 combination therapy, and the ineffectiveness of PD-1 combined with chemotherapy in patients with low or negative CPS scores. To tackle these challenges, the researchers innovatively employed a domestically developed PD-1/CTLA-4 dual-target antibody in the COMPASSION-04 study, marking the first clinical trial globally to evaluate this combination as a first-line treatment for advanced gastric cancer.
ESMO China’s Voice | Dr. Yuhong Zhou: Surufatinib Combined with Gemcitabine in Second-Line Treatment Shows Promise for Improving Prognosis in Soft Tissue Sarcoma

ESMO China’s Voice | Dr. Yuhong Zhou: Surufatinib Combined with Gemcitabine in Second-Line Treatment Shows Promise for Improving Prognosis in Soft Tissue Sarcoma

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting recently concluded in Barcelona, Spain, bringing together the world's leading oncology experts. At this year's conference, Dr. Yuhong Zhou from Zhongshan Hospital, Fudan University, presented a phase II multicenter clinical trial that explored the efficacy and safety of surufatinib combined with gemcitabine in soft tissue sarcoma (STS) patients who had failed anthracycline chemotherapy or anlotinib monotherapy. The study offers new perspectives for clinical practice.
ESMO Global Perspective | Prof. Xichun Hu, Prof. Linda, Prof. Esteller, and Prof. Qinghua Xu: New Advances in CUP Treatment and Prospects

ESMO Global Perspective | Prof. Xichun Hu, Prof. Linda, Prof. Esteller, and Prof. Qinghua Xu: New Advances in CUP Treatment and Prospects

With the rapid development of genetic testing technology, the treatment strategies for patients with cancer of unknown primary (CUP) are undergoing revolutionary changes. During the 2024 ESMO Congress, the World CUP Alliance held a special "Roundtable on Access & Awareness of Precision Oncology" at the ESMO Congress, looking forward to the current treatment of CUP patients. After the meeting, Oncology Frontier specially invited Prof. Xichun Hu from Fudan University Shanghai Cancer Center, Prof. Linda Mileshkin from Peter MacCallum Cancer Center in Australia, Prof. Manel Esteller from Josep Carreras Leukemia Research Institute in Spain, and Prof. Qinghua Xu from Hangzhou Gene Help Technology Co., Ltd Help to gather together and discuss in depth the new advances in the treatment of CUP. From the positive data of the CUPISCO trial to the results of the Fudan CUP-001 study, the experts not only shared cutting-edge research results but also proposed valuable insights on how to improve the diagnostic accuracy for CUP patients and promote the implementation of personalized treatment plans, bringing new treatment hopes for CUP patients worldwide.
Dr. Wei Sang: Analysis of CAR-T Efficacy and Challenges in Various Hematologic Malignancies at the 5th Tianjin International Lymphoma Conference

Dr. Wei Sang: Analysis of CAR-T Efficacy and Challenges in Various Hematologic Malignancies at the 5th Tianjin International Lymphoma Conference

From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was successfully held. The conference featured 12 specialized sessions, including immunotherapy, translational research, and new drug development, creating a platform for international academic exchange and cooperation. During the event, Hematology Frontier invited Dr. Wei Sang from The Affiliated Hospital of Xuzhou Medical University to provide an in-depth analysis of CAR-T cell therapy in different hematologic malignancies and explore strategies for optimizing treatment outcomes.
EBMT China’s Voice | Professors Xiaoyan Ke and Kai Hu’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients

EBMT China’s Voice | Professors Xiaoyan Ke and Kai Hu’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients

The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from April 14th to 17th in Glasgow, United Kingdom, showcasing the latest advancements in stem cell transplantation and cell therapy. These advancements are driving better clinical outcomes for patients with hematological diseases and blood cancers. At this year's conference, two studies conducted by Professor Xiaoyan Ke from Peking University Third Hospital/Beijing Chaoyang Hospital and Professor Kai Hu from Beijing Chaoyang Hospital were presented, highlighting how combined autologous hematopoietic stem cell transplantation and CAR-T cell therapy can improve survival rates for lymphoma and multiple myeloma patients.
Professor Baohui Han: Strategically Analyzing ASCO’s ADC Developments in NSCLC and Planning for Future Progress

Professor Baohui Han: Strategically Analyzing ASCO’s ADC Developments in NSCLC and Planning for Future Progress

On July 2, 2024, the "ADC High-Level Closed-Door Seminar," chaired by Vice President Yong Yang of China Pharmaceutical University and President Jin Li of Shanghai Gaobo Oncology Hospital, was grandly held in Shanghai. The seminar explored the current status and future of ADC development. During the event, Oncology Frontier interviewed Professor Baohui Han from the Shanghai Chest Hospital . Combining recent ASCO conference updates, Professor Han analyzed the efficacy results and safety management points of ADC treatment in NSCLC and shared insights on the future prospects of ADC development.
Annual Review | Academician Xu Zhang: Chinese Doctors Leading a New Revolution in Urological Surgery Innovation

Annual Review | Academician Xu Zhang: Chinese Doctors Leading a New Revolution in Urological Surgery Innovation

Time rewards those who strive, and success comes to those who persevere. As 2023 draws to a close, the year has left behind many noteworthy achievements in China’s field of urology, especially in the areas of prostate cancer surgery and drug treatments. On this occasion, Urology Frontier interviewed Xu Zhang, Academician of the Chinese PLA General Hospital and a pioneer in laparoscopic techniques in China’s urological surgery. In this interview, he shared significant developments in surgical and medical treatments for prostate cancer over the past year.